“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like GlaxoSmithKline's Nucala Wins FDA Approval for EGPA December 11, 2017 Valeant to Shave an Additional $200M From Its Mountain of Debt January 25, 2018 Medtronic Orders Employees to Evacuate California Facilities October 9, 2017
